Dr. Mark A. Tulli, MD
Interventional Cardiology (Interventional Cardiology Physician)
- Medicare participating
At a glance
- Medical school
- Pennsylvania State University College of Medicine (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,503
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: Pennsylvania State University College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Interventional Cardiology Physician primary
FL license ME96062
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- HCA Florida North Florida Hospital Gainesville, FL
- HCA Florida Lake City Hospital Lake City, FL
Medical groups
- Interventional Cardiologists of Gainesville, PA (36 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,503
- Services billed
- 6,407
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 1,166 | 931 |
| Established patient office or other outpatient visit, 30-39 minutes | 932 | 781 |
| Injection, regadenoson, 0.1 mg | 472 | 118 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 397 | 391 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 213 | 77 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 194 | 97 |
| Ultrasound of both sides of head and neck blood flow | 165 | 164 |
| Established patient office or other outpatient visit, 40-54 minutes | 164 | 151 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 158 | 108 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 136 | 136 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Metoprolol Succinate Other prescribers in Gainesville, FL | 373 |
| Eliquis (apixaban) Other prescribers in Gainesville, FL | 367 |
| Atorvastatin Calcium Other prescribers in Gainesville, FL | 362 |
| Carvedilol Other prescribers in Gainesville, FL | 210 |
| Amlodipine Besylate Other prescribers in Gainesville, FL | 194 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Gainesville, FL | 168 |
| Repatha Sureclick (evolocumab) Other prescribers in Gainesville, FL | 163 |
| Entresto (sacubitril/valsartan) Other prescribers in Gainesville, FL | 155 |
| Jardiance (empagliflozin) Other prescribers in Gainesville, FL | 130 |
| Rosuvastatin Calcium Other prescribers in Gainesville, FL | 123 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 17 payments worth $808 in total to this clinician.
| Abiomed | $261 |
|---|---|
| Abbott Laboratories | $137 |
| Stryker Corporation | $134 |
| Novartis Pharmaceuticals Corporation | $48.38 |
| Boston Scientific Corporation | $45.71 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $41.61 |
| Angiodynamics, Inc. | $31.54 |
| Amgen Inc. | $21.27 |
| Food and Beverage | $808 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $7,500 in research payments for these studies, mostly to the institutions running them.
- Prevail Global
Medtronic, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.